Aakaar Medical Technologies Limited IPO Details

1. A substantial portion of the revenue is derived from sale of imported third party manufactured brands which exposes it to various risk.

2. The company relies on third party contract manufacturers (domestic and international) & loan licensing partners for manufacturing products & devices which of the sell under its own Brand. the company dependence on third-party manufacturers for the manufacturing of all the products subjects it to certain risks, which, if realized, could adversely affect its business, results of operations, cash flows and financial condition.

3. The company registered office is situated in Maharashtra and the derive a significant portion of the company revenue from state of Maharashtra and Karnataka, making it vulnerable to geographical concentration risk.

4. The company has appointed Parekh Integrated Services Private Limited (PISPL) as a CSA agent for storing, delivering and distributing its products & recovery of dues. Any non-performance or breach of covenants of the CSA agreement executed with PISPL may adversely affect its business operations, profitability and cash flows.

5. Failures to identify and effectively respond to changing consumer preferences, consumer behaviour and spending patterns or changing beauty and personal care trends in a timely manner, may adversely affect the demand for the company products, causing its business, results of operations, financial condition and cash flows.

6. The company may not be able to accurately manage the company inventory, this may adversely affect its business, financial condition and results of operations and reputation.

7. The Company has reported negative cash flow in the past. Any negative cash flows in the future would adversely affect the cash flow requirements, which may adversely affect the company ability to operate the company business and implement its growth plans, thereby affecting its financial condition.

8. As the market for aesthetic treatments grows, the number of clinics and practitioners offering these services is increasing in India which may increase competition among clinics leading to competitive pricing of products. Any change in product pricing will impact revenue and profitability of the business.

9. Its may be subject to unfair competitive or trade practices, like the availability of counterfeit injectables, skincare products, and aesthetic devices, which may reduce the company sales and harm its brands, adversely affecting the company business, financial condition, cash flows and results of operations.

10. Invasive and non-invasive procedures alike carry risks, including infections, scarring, and unintended aesthetic outcomes which may deter the patients from seeking treatments and impact the demand for the products and devices used for these treatments.